Endpoint Welcomes Rob Friederichs: Driving Medical Device Strategy and Program Design

May 5, 2025

With 15 years of experience in cardiovascular device development and preclinical program strategy, Dr. Rob Friederichs brings a results-driven approach to advancing study design, model development, and experimental execution. His expertise helps early-stage teams transform complex technical challenges into clear, actionable plans that accelerate innovation.

Endpoint Preclinical is proud to welcome Dr. Rob Friederichs, PhD, to our Expert Network. A versatile preclinical strategist, Rob has spent over a decade guiding novel therapies from concept to first-in-human use. His strength lies in designing hypothesis-driven studies, optimizing experimental models, and assembling the right expertise to fast-track product advancement and de-risk innovation. View Rob’s Profile

Throughout his career, Rob has demonstrated a unique ability to bridge technical complexity with practical execution. His contributions include advancing structural heart procedures, pioneering CT-planned interventional surgeries, and driving innovation in model development. He has built cadaver models and ex vivo flow systems to address boundary-condition and failure-mode questions critical to device development.

Rob is also highly skilled in multimodal imaging, utilizing CT, TEE, IVUS, OCT, and MRI data analysis to assess device performance and physiological dynamics. His ability to quantify complex interactions between devices and biological systems strengthens both study outcomes and clinical translation.

Beyond technical execution, Rob brings deep experience in regulatory assessment, having crafted GLP-compliant protocols, defended data to global regulators, and delivered concise, decision-ready reports. His work balances scientific rigor, operational efficiency, and real-world relevance—empowering teams to move confidently through verification, validation, and clinical milestones.

My commitment to scientific research is deeply personal. Having seen my wife’s life saved by an innovative medical device, I understand firsthand the real-world impact of rigorous preclinical research. I believe clear problem definition, thoughtful planning, and agile collaboration are essential to delivering safe, effective therapies—and I bring that perspective to every project I undertake. — Rob Friederichs, PhD

At Endpoint Preclinical, Rob will serve as an Advanced Study Coordinator, partnering with clients to plan robust studies, optimize experimental models, define endpoints, and integrate cross-functional expertise across the Endpoint network. His role will also extend to training services, supporting clients in refining study design, imaging workflows, and procedural execution to maximize reproducibility and study impact.

We are thrilled to welcome Dr. Rob Friederichs to Endpoint Preclinical. His experience, strategic mindset, and personal commitment to advancing patient care will strengthen our ability to deliver high-quality preclinical research services and support medical innovation.

To learn how Rob can help accelerate your next preclinical project, contact us today.